オレキシンAのプロラクチン分泌への影響とBMP-4の関与：ラット下垂体細胞を用いた検討 by Fujisawa, Satoshi
  - 1 - 
 
Orexin A modulates prolactin production by regulating BMP-4 
activity in rat pituitary lactotorope cells. 
 
Satoshi Fujisawa1, Motoshi Komatsubara1, Kanako Ogura-Ochi1, Naoko 
Tsukamoto-Yamauchi1, Kishio Toma1, Kenichi Inagaki1, Jun Wada1 and Fumio 
Otsuka2 
 
1Department of Nephrology, Rheumatology, Endocrinology and Metabolism and 
2Department of General Medicine, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 
 
Short title: Orexin modulates prolactin transcription.  
Key words: Bone morphogenetic protein, Lactotrope, Orexin, Pituitary, and 
Prolactin.  
 
Disclosure Statement:  There is nothing to disclose. 
Abbreviations:  AC, adenylyl cyclase; ActRІІ, activin type ІІ receptor; ALK, 
activin receptor-like kinase; BMP, bone morphogenetic protein; BMPRІІ, BMP 
type ІІ receptor; Dor, dorsomorphin; DORA, dual ORX receptor antagonist; ER, 
estrogen receptor; FSH, follicle-stimulating hormone; FSK, forskolin; LDN, 
LDN193189; ORX, orexin A; OX1R, orexin type 1 receptor; OX2R, orexin type 2 
receptor; and PRL, prolactin.  
 
Correspondence to: Fumio OTSUKA, M.D., Ph.D. 
Department of General Medicine, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, 
Okayama 700-8558, Japan.  Phone: +81-86-235-7342, Fax: +81-86-222-7345  
E-mail: fumiotsu@md.okayama-u.ac.jp 
 
  - 2 - 
Abstract 
 
The impact of orexins on anterior pituitary function has yet to be clarified.  
We studied the effects of orexin A and its interaction with the bone morphogenetic 
protein (BMP) system on the regulatory role of prolactin synthesis using rat 
lactotrope GH3 cells expressing BMP-4.  Orexin type 1 receptor (OX1R), but not 
type 2 receptor (OX2R), was predominantly expressed in GH3 cells.  Orexin A 
suppressed forskolin-induced, but not basal, prolactin mRNA expression without 
reducing cAMP levels.  Of note, orexin A suppressed BMP-4-induced prolactin 
mRNA and cAMP synthesis.  Impairment of the effects of orexin by chemical 
inhibitors suggested involvement of the P38 pathway in the OX1R activity that 
suppresses BMP-4-induced PRL expression.  Given that inhibition of BMP-
receptor signaling reduced prolactin mRNA levels, endogenous BMP action is 
likely to be linked to the activation of prolactin synthesis by GH3 cells.  Orexin A 
was revealed to suppress Smad1/5/9 phosphorylation and Id-1 transcription 
induced by BMP-4, which was restored in the presence of orexin-receptor 
antagonists, suggesting that the inhibitory effect of orexin A occurred via OX1R.  
Orexin A also reduced ALK-3 expression but increased inhibitory Smad6/7 
expression, while BMP-4 treatment downregulated OX1R expression.  These 
results indicated that orexin A plays an inhibitory role in prolactin production 
through suppression of endogenous BMP activity in GH3 cells, suggesting that a 
new functional role of the interaction between orexin and BMP-4 is modulation of 
prolactin levels in lactotrope cells.  
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Introduction 
 
Orexins, including orexin A and orexin B, are neuropeptides that are 
mainly synthesized in the hypothalamus and produced from the common 
precursor preproorexin, [1, 2].  Orexins have specific affinities to two different 
receptors coupled with G-proteins, named orexin type 1 and orexin type 2 
receptors (OX1R and OX2R).  OX1R selectively binds orexin A, while OX2R can 
bind both orexin A and orexin B with similar affinities [3].  Orexins have important 
functions in the regulation of sleep-wake balance, energy expenditure and intake 
of food.  The expression of orexins and their receptors has been found in various 
peripheral tissues [4] and also in many endocrine tissues such as the adrenal, 
testis, ovary and pituitary [5].   
Orexins are functionally linked to the regulation of endocrine activities 
including the hypothalamic-pituitary-adrenal and -gonadal axes [6, 7] and growth 
hormone control [8].  Orexin receptors were shown to be expressed in the rat 
[9], porcine [10] and human pituitaries [11]; however, the effects of orexin on 
prolactin (PRL) synthesis and the regulatory roles in lactotorope cells have not 
been clarified.  Intra-ventricular administration of orexin reduced the plasma 
concentration of PRL in experiments using rats [12, 13], and the action of orexin 
was shown to be mediated by tubero-infundibular dopaminergic neurons (TIDA) 
in the hypothalamus [14]. 
There has been accumulating evidence that bone morphogenetic proteins 
(BMPs), produced as autocrine and/or paracrine factors, play key roles in the 
differentiation of pituitary cells [15-18].  Interestingly, BMP-4, which induces key 
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organogenetic actions in the anterior pituitary, has also been shown to have 
various functions in the pathogenesis of differentiated pituitary tumors including 
corticotropinomas [16] and prolactinomas [19-21].  It has also been revealed 
that there is a functional interrelationship between the BMP-4-Smad pathway and 
estrogen receptor (ER) signaling in the pathogenesis of PRL-producing pituitary 
adenomas and in the regulation of PRL transcription [22, 23].   
In the present study, we studied the activities of orexin by focusing on 
BMP-4, which can facilitate PRL production and is also involved in the 
aggressiveness of prolactinomas, in regard to the modulation of PRL secretion 
by lactotrope cells.  A modulatory effect of orexin on PRL production and mutual 
interaction of orexin and the BMP system were revealed.   
 
Materials and Methods 
 
Experimental Reagents 
A mixture of Dulbecco’s Modified Eagle’s Medium/Ham F-12 medium 
(DMEM/F12), forskolin (FSK), 3-isobutyl-1-methylxanthine (IBMX) and H-89 
(cAMP-dependent protein kinase inhibitor) were purchased from Sigma-Aldrich 
Corp. (St. Louis, MO).  Recombinant human BMP-4 from R&D Systems Inc. 
(Minneapolis, MN) and the BMP-receptor signaling inhibitors LDN193189, from 
Stemgent (San Diego, CA), and dorsomorphin, from Calbiochem (San Diego, 
CA), were used in the experiments.  The ERK inhibitor U0126 and the P38-
MAPK inhibitor SB203580 were from Promega Corp. (Madison, WI), and the 
stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) inhibitor 
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SP600125 was from Biomol Lab. Inc. (Plymouth Meeting, PA).  Human orexin A 
was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), the 
dual orexin-receptor antagonist DORA-12 [24] was provided by Merck Sharp & 
Dohme Corp. (Rahway, NJ), and the selective non-peptide OX1R antagonist 
SB408124 [25] was purchased from Tocris Bioscience (Bristol, UK). 
 
GH3 cell culture and measurement of cAMP levels 
Rat pituitary tumor GH3 cells (5 × 104 viable cells), originally provided by 
Prof. Joseph A. Majzoub, Children's Hospital, Harvard Medical School, were 
cultured in DMEM/F12 supplemented with 10% fetal calf serum (FCS) and 
antibiotics in 24-well plates under a 5% CO2 atmosphere at 37C.  After 
preculture with the growth medium, the medium was changed to a serum-free 
medium containing 0.1 mM IBMX, an inhibitor of phosphodiesterase activity, and 
the GH3 cells were treated with the indicated concentrations of orexin A in 
combination with FSK or BMP-4 for 24 h.  The culture medium was then 
collected and the supernatant of the centrifuged medium was collected and 
stored at -80C until measurement.  The extracellular contents of cAMP were 
determined by an enzyme immunoassay (ELISA; Enzo Life Sciences, Inc., NY, 
USA).   
 
RNA extraction, reverse transcription (RT) and real-time PCR 
After preculture, cells (1 × 105 viable cells) were treated with the indicated 
concentrations of orexin A in combination with FSK or BMP-4 in the presence or 
absence of LDN193189, dorsomorphin, orexin receptor inhibitors (DORA-12 and 
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SB408124), MAPK inhibitors (U0126, SB203580 and SP600125) or H-89 in 12-
well plates in a serum-free condition for 24 h.  The culture medium was then 
removed and total cellular RNA was extracted using TRI Reagent® (Cosmo Bio 
Co., Ltd., Tokyo, Japan).  Whole tissues of the normal rat pituitary were obtained 
from 8-week-old female Wistar rats and total RNA was also extracted using TRI 
Reagent®.  Primer pairs for PCR were selected from different exons of the 
corresponding genes as follows: rat PRL: 271-291 and 471-491 (NM_012629); 
rat Id-1: 218-240 and 357-377 (NM_012797); rat OX1R: 1658-1680 and 2057-
2079 (NM_013064); rat OX2R: 209-233 and 539-558 (NM_013074); rat BMP-4: 
500-521 and 705-724 (NM_012827.2); and rat BMP type II receptor (BMPRII): 
1785-1804 and 1942-1961 (NM_080407).  Rat Smad6, Smad7, ALK-2, ALK-3 
and ribosomal protein L19 (RPL19) were selected as we reported previously [26].  
The extracted RNA (1 μg) was subjected to an RT reaction using ReverTra Ace® 
(TOYOBO CO., LTD., Osaka, Japan) with a random hexamer and 
deoxynucleotide triphosphate (dNTP).  After optimizing the annealing conditions 
for each pair of primers, quantitative PCR (qPCR) was performed to quantify the 
level of target gene mRNA using the LightCycler® Nano real-time PCR system 
(Roche Diagnostic Co., Tokyo, Japan).  The relative expression of each mRNA 
was determined by the ΔCt method, in which ΔCt was the value obtained by 
subtracting the Ct value of RPL19 mRNA from that of the target mRNA.  The 
amount of target mRNA relative to RPL19 mRNA was expressed as 2-(ΔCt), and 
the results were expressed as the ratio of target mRNA to RPL19 mRNA.    
 
Western blots 
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GH3 cells (1 × 105 viable cells) were precultured with DMEM/F12 
containing 10% FCS and antibiotics in 12-well plates.  The growth medium was 
then changed to a serum-free medium and treated with the indicated 
concentrations of orexin A for 24 h.  Subsequently, the cells were stimulated with 
indicated concentrations of BMP-4 for 60 to 120 min.  The treated cells were 
solubilized in 100 μl RIPA lysis buffer (Upstate Biotechnology, Lake Placid, NY) 
containing 1 mM Na3VO4, 1 mM NaF, 2% SDS, and 4% β-mercaptoethanol.  
Western blot analysis was performed using the cell lysates with specific 
antibodies against phospho-Smad1/5/9 (pSmad1/5/9), total-Smad1 (tSmad1; 
Cell Signaling Technology, Inc., Beverly, MA) and actin (Sigma-Aldrich Co. Ltd.).  
The blotted bands were analyzed by the C-DiGit® Blot Scanner System (LI-COR 
Biosciences, NE) by scanning the integrated signal intensities.  For evaluating 
the phosphorylated Smad contents, the ratios of the digitized levels of 
pSmad/tSmad bands were calculated. 
 
Statistics 
Experimental results are shown as means ± SEM of data from at least 
three independent experiments, each performed with triplicate samples.  The 
data were then subjected to ANOVA followed by Tukey-Kramer’s post hoc test or 
unpaired t-test (StatView 5.0 software, Abacus Concepts, Inc., Berkeley, CA).  P 
values <0.05 were accepted as statistically significant.   
 
Results 
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Firstly, we assessed the expression of orexin receptors in rat whole 
pituitary tissues and GH3 cells.  The expression of both OX1R and OX2R was 
detected in the rat whole pituitary by RT-PCR as shown in Fig. 1A, whereas the 
major orexin receptor for GH3 cells was found to be OX1R.  In GH3 cells, BMP-
4 expression was also detected by RT-PCR as seen in the rat whole pituitary (Fig. 
1A).  Treatment with orexin A (10-300 nM) did not change basal mRNA levels 
of PRL for 24 h as shown in Fig. 1B.  FSK (0.3 M) treatment significantly 
enhanced mRNA expression of PRL, which was significantly suppressed by co-
treatment with orexin A (100 to 300 nM).  To investigate the mechanism by 
which orexin A suppressed FSK-induced PRL synthesis, changes of cAMP levels 
were examined.  As shown in Fig. 1C, orexin A failed to suppress basal and 
FSK (0.01-0.3 M)-induced cAMP synthesis. 
 PRL synthesis is known to be induced by BMP-4 treatment in lactotorope 
cells, and it is thought that crosstalk between Smad and ER complex [23] and 
increase in cellular cAMP induction [19] are involved.  We therefore examined 
the functional interrelationship between BMP-4 and orexin in GH3 cells.  As 
shown in Fig. 2A, treatment with BMP-4 (10 ng/ml) significantly enhanced PRL 
mRNA expression and co-treatment with orexin A (100 nM) suppressed the 
enhancement of PRL expression.  Furthermore, treatment with orexin A 
significantly reduced BMP-4-induced cAMP levels in 24-h culture, while orexin A 
failed to suppress basal cAMP synthesis (Fig. 2B).  To examine the role of the 
activity of endogenous BMP expressed in GH3 cells [26], a BMP-receptor signal 
inhibitor, dorsomorphin, that selectively inhibits ALK-2, -3 and -6 signaling [27] 
and another inhibitor, LDN193189, that specifically inhibits ALK-2 and -3 actions 
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[28] were used to inhibit endogenous BMP actions.  As shown in Fig. 2C, co-
treatment with LDN193189 or dorsomorphin (100-300 nM) reduced basal and 
FSK-induced levels of PRL mRNA in 24-h culture, indicating that endogenous 
BMPs augment PRL synthesis by GH3 cells. 
Furthermore, to determine the possible signaling pathways of orexin for 
suppressing BMP-4-induced PRL expression, specific inhibitors (1 M) for cAMP-
PKA and MAPKs were used for examining the changes of PRL mRNA levels.  
As shown in Fig. 2D, treatment with a P38 inhibitor, SB203580, abolished the 
suppressive effect of orexin A on BMP-4-induced PRL expression in 24-h culture, 
whereas treatments with a cAMP-PKA inhibitor, H-89, an ERK inhibitor, U0126, 
and a SAPK/JNK inhibitor, SP600125, did not affect the action of orexin.  These 
results suggested that P38 signaling is, at least in part, involved in the orexin 
receptor activity for regulating BMP-4-induced PRL expression in GH3 cells. 
Next, we examined the involvement of orexin action in the intracellular 
signaling of BMP-4.  Stimulation with BMP-4 (10 ng/ml) for 2 h readily activated 
Smad1/5/9 phosphorylation in GH3 cells as shown in Fig. 3A.  Importantly, 
orexin A (100 nM) pretreatment for 24 h suppressed Smad1/5/9 phosphorylation 
induced by BMP-4 (Fig. 3A), suggesting that orexin A suppresses PRL 
production by reducing Smad1/5/9 activation in GH3 cells.  To clarify the effects 
of the orexin receptor on BMP-signaling, mRNA levels of Id-1, the target gene of 
BMP-receptor signaling, were examined.  As shown in Fig. 3B, treatment with 
BMP-4 (1 ng/ml) significantly upregulated Id-1 mRNA for 24 h, and the expression 
was significantly inhibited by co-treatment with orexin A (100 nM).   Of note, 
treatment with the dual orexin receptor antagonist DORA-12 (10 µM) and the 
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selective OX1R antagonist SB408124 (10 µM) restored the suppressive effect of 
orexin on Id-1 mRNA expression induced by BMP-4 (Fig. 3B), suggesting that 
OX1R action is functionally linked to the suppression of BMP-Smad signaling in 
GH3 cells.  To determine the role of OX1R function in GH3 cells, changes of 
OX1R mRNA in the presence of BMP-4 were also examined.  As shown in Fig. 
3C, addition of BMP-4 (10 ng/ml) downregulated OX1R mRNA expression for 24 
h, suggesting that there is a counter-regulatory effect of BMP-4 for controlling 
PRL level via OX1R action. 
To try to determine the underlying mechanism by which orexin A inhibits 
BMP-receptor signaling, the expression levels of BMP-receptor components 
were also examined by real-time PCR.  As shown in Fig. 4A, cell culture with 
orexin A (100 nM) for 24 h reduced the expression levels of ALK-3 among the 
BMP-4 receptors expressed in GH3 cells, including ALK-2, ALK-3 and type II 
receptor BMPRII [26].  We next examined the effects of orexin A on the 
expression of inhibitory Smads.  Since it is known that the expression of 
inhibitory Smad6/7 can be induced by stimulation of BMPs in various BMP-
responsive cells [29-32], Smad6/7 mRNA levels were evaluated in GH3 cells in 
the presence of BMP-4 (10 ng/ml).  As a result, treatment with orexin A (100 nM) 
significantly enhanced the mRNA expression of inhibitory Smad6 and Smad7 
induced by BMP-4 (10 ng/ml) for 24 h (Fig. 4B).  These findings suggested that 
OX1R signaling plays an inhibitory role in BMP-Smad signaling in GH3 cells via 
downregulation of BMP receptors and upregulation of inhibitory Smad6/7.      
       
Discussion 
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Here we demonstrated a functional interaction between orexin A and BMP-
4 in PRL secretion by pituitary lactotrope GH3 cells (Fig. 5).  OX1R was 
expressed more dominantly than OX2R in GH3 cells, and OX1R activation 
induced by orexin A suppressed FSK- and BMP-4-induced PRL mRNA 
expression.  Since orexin A treatment suppressed BMP-4-induced cAMP 
synthesis but not FSK-induced cAMP synthesis, the mechanism by which orexin 
A suppressed FSK-induced PRL expression is directly linked to BMP activity 
rather than the cAMP-PKA pathway in GH3 cells.  Given that ALK inhibitors 
suppressed PRL expression, endogenous BMP action seems to upregulate PRL 
synthesis in an autocrine manner.  Orexin A suppresses endogenous BMP 
activity in GH3 cells, leading to a reduction of FSK-induced PRL expression.  It 
was of interest that orexin A treatment suppressed BMP-4-induced Smad1/5/9 
signaling and Id-1 transcription via OX1R.  It was also revealed that BMP 
signaling in GH3 cells was modulated by orexin A through suppression of BMP 
type-I receptor expression as well as upregulation of inhibitory Smad6/7.   
Treatment with BMP-4, in turn, suppressed OX1R expression, implying the 
presence of regulatory interaction of orexin and BMP-signaling in GH3 cells. (Fig. 
5).   
OX1R mRNA is expressed at a higher level than that of OX2R in the rat 
pituitary, and OX1R mRNA levels were significantly higher in male rats than in 
female rats [33].  Both OX1R mRNA and OX2R mRNA were expressed 
abundantly in the intermediate lobe in the rat pituitary, whereas OX1R was 
expressed more strongly than OX2R in the anterior lobe [9].  Immunofluorence 
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analysis revealed that OX1R was present in acidophil cells that co-express GH, 
while OX2R was present in basophil cells that co-express ACTH [11].  In 
addition, in the Xenopus pituitary, OX1R was shown to be distributed in PRL-
containing cells [34].  However, the physiological effect of orexin on PRL 
secretion in pituitary cells has remained controversial.   In rat pituitary primary 
culture cells, orexin A did not affect PRL secretion [35], whereas Molik et al. found 
by using ovine cultured pituitary cells that PRL secretion in response to orexin A 
changed depending on the length of day [36].  Also, sheep PRL secretion was 
negatively responsive to orexin A during a short day, whereas orexin enhanced 
PRL secretion during a long day [36].  Given that the circadian modulator 
melatonin and Clock gene were shown to be linked to the regulation of PRL 
secretion via the function of BMP-4 [20], a new interaction between BMP-4 and 
orexin signaling might also be involved in control of the circadian profile of PRL 
secretion. 
BMPs were originally recognized as factors for bone formation, but many 
physiological actions of BMPs in various endocrine tissues, including the ovary, 
pituitary, adrenal and thyroid, have been revealed [37, 38].  We earlier reported 
that rat lactotrope GH3 cells express BMP ligands including BMP-4 and -6, BMP 
type I (ALK-2, -3 and -4) and type II (ActRII, ActRIIB and BMPRII) receptors, and 
Smads (Smad1 to 8) [26].  We previously found that the BMP system is involved 
in PRL regulation by somatostatin analogs [19].  In addition, we reported that 
melatonin, related to the formation of circadian and seasonal rhythms, 
suppressed PRL production by inhibiting Smad signaling and cAMP synthesis 
[21].  BMPs have also been shown to be linked to follicle-stimulating hormone 
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(FSH) and luteinizing hormone secretion in gonadotropes cells [31, 39-42] and to 
the regulation of adrenocorticotropin produced by corticotrope cells [16, 43]. 
Orexins were originally identified as neuropeptides in the hypothalamus, 
and attention has been paid to the localization where the orexin ligands can be 
produced and supplied for the pituitary.  Preproorexin mRNA was not detected 
in the rat pituitary, as previously reported [33]; however, orexin nerve fibers and 
orexin ligands were abundantly expressed in the rat median eminence and 
posterior lobe of the pituitary [9].  Immunofluorence analyses demonstrated the 
presence of both orexin A and orexin B in the human pituitary, wherein orexin A 
was distributed diffusely in the anterior pituitary and detected in more than 80% 
of lactotrope cells, and orexin B was found in all corticotrope cells. [44].  The 
existence of a low concentration of orexin A in human plasma has also been 
reported, and the levels apt to be affected by alteration of the energy status and 
body composition [4].  These results indicate the existence of circulating orexin 
from the hypothalamus via the pituitary portal artery or other peripheral tissues, 
although the source of orexin ligands remains unknown. 
The present study demonstrated a physiological interaction of the orexin 
system and BMP signaling in lactotrope cells.  Expression profiling analysis 
indicated that BMP-Smad signaling is one of the pathways regulated by orexin 
signaling [45].  In this regard, a novel effect of orexin on steroidogenesis of rat 
granulosa cells was uncovered by our recent approach [32].  It was found in that 
study that orexin A suppressed Smad-signaling by suppressing BMP receptors 
and by upregulating Smad6/7, which led to enhancement of FSH-induced 
progesterone synthesis [32].  Those findings are similar to the results of the 
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present study, implying that a functional link between the effects of orexin and 
BMPR signaling plays a key role in regulating hormonal homeostasis in various 
tissues.  Considering that orexin A exerted inhibitory effects on BMP-4-induced 
PRL expression, orexin might also contribute to the formation of diurnal rhythm 
involving PRL secretion through regulation of BMP-4 activity in an in vivo situation.  
In the present study, a putative signaling of OX1R was indicated to be the P38-
MAPK pathway based on the results of chemical inhibition experiments.  
However, the detailed mechanism by which OX1R activation suppresses BMP-
4-induced PRL expression remains uncertain, and other pathways including PLC, 
PKC and intracellular Ca++ induction could also be involved in this activity [3]. 
Collectively, the results of the present study suggest that orexin A has an 
inhibitory role in PRL synthesis in the presence of PRL secretory factors.  This 
may also be associated with circadian secretion of PRL.  The results suggested 
that orexin plays a functional role as a modulator for BMP-4 activity that can 
facilitate PRL secretion (Fig. 5).  From a clinical viewpoint, the findings may be 
applicable to treatment of prolactinomas, the most frequent functioning pituitary 
adenomas.  Although dopamine agonists are widely and effectively used to treat 
most prolactinomas, some cases are resistant to treatment and some may recur 
[46].  Control of the endogenous BMP system that induces PRL secretion and 
an attempt to upregulate endogenous orexin activity might be a possible strategy 
for controlling prolactinomas.  
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Figure Legends: 
 
Fig. 1. Expression of orexin receptors and effect of orexin A on PRL 
expression induced by FSK in GH3 cells.  A) The expression of mRNAs 
encoding OX1R, OX2R, BMP-4 and RPL19 was examined by RT-PCR in GH3 
cells compared with rat whole pituitary tissues.  MM: molecular weight marker.  
B) After preculture, GH3 cells (1 × 105 cells/well) were treated with forskolin (FSK) 
and orexin A (ORX) in serum-free media.  After 24-h culture, total cellular RNA 
was extracted and the mRNA expression levels of PRL were quantified by qPCR.  
The expression levels of target genes were standardized by the RPL19 level in 
each sample.  C) After preculture, cells (5  104 cells/well) were treated with the 
combination of ORX and FSK in serum-free media containing 0.1 mM of IBMX.  
After 24-h culture, the supernatants of culture media were collected and cAMP 
levels were determined using ELISA.  Results are shown as means ± SEM of 
data from at least three independent experiments with triplicated samples (B: 
n=9; C: n=6).  Statistical analysis was performed by ANOVA.  P values <0.05 
were accepted as statistically significant.  Values with different superscript 
letters are significantly different at P < 0.05. 
 
Fig. 2. Effects of orexin A on BMP-4-induced PRL expression and 
involvement of endogenous BMP action in GH3 cells.  A, C, D) After 
preculture, GH3 cells (1 × 105 cells/well) were treated with ORX, BMP-4, FSK, 
and various signal inhibitors, LDN193189 (LDN), dorsomorphin (Dor), U0126, 
SB203580, SP600125 and H-89, in serum-free media.  After 24-h culture, total 
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cellular RNA was extracted and the mRNA expression levels of PRL were 
quantified by qPCR.  The expression levels of target genes were standardized 
by the RPL19 level in each sample.  B) After preculture, cells (5  104 cells/well) 
were treated with ORX and BMP-4 in serum-free media containing 0.1 mM of 
IBMX.  After 24-h culture, supernatants of the culture media were collected, and 
cAMP levels were determined using ELISA.  Results are shown as means ± 
SEM of data from at least three independent experiments with triplicated samples 
(A: n=14; B: n=6; C: n=9; D: n=15).  Statistical analysis was performed by 
ANOVA (A, B, D) and unpaired t-test (C).  P values <0.05 were accepted as 
statistically significant.  Values with different superscript letters are significantly 
different at P < 0.05.  **P < 0.01 and *P < 0.05 vs. corresponding control groups, 
and #P < 0.05 vs. BMP-4-treated group. 
 
Fig. 3. Effects of orexin A on BMP-receptor signaling in GH3 cells.  A) GH3 
cells (1 × 105 cells/well) were pretreated with ORX in serum-free media for 24 h.  
After 2-h stimulation with BMP-4, the cell lysates were subjected to immunoblot 
(IB) analysis using antibodies that detect pSmad1/5/9, tSmad1 and actin.  B, C) 
Cells (1  105 cells/well) were treated with BMP-4, ORX, a dual ORX receptor 
antagonist (DORA-12), and an OX1R-selective antagonist (SB408124) in serum-
free conditions for 24 h.  Total cellular RNAs were extracted and the mRNA 
levels of Id-1 and OX1R were examined by qPCR.  The expression levels of 
target genes were standardized by the RPL19 level in each sample.  Results are 
shown as means ± SEM of data from at least three independent experiments with 
triplicated samples (A: n=7; B: n=15; C: n=11).  Statistical analysis was 
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performed by ANOVA (A, B) and unpaired t-test (C).  P values <0.05 were 
accepted as statistically significant.  Values with different superscript letters are 
significantly different at P < 0.05.  *P < 0.05 vs. between the indicated groups.  
 
Fig. 4. Effects of orexin A on the expression of genes involved in BMP-
receptor signaling in GH3 cells.  GH3 cells (1 × 105 cells/well) were treated 
with ORX (A) and the combination of ORX and BMP-4 (B).  After 24-h culture, 
total cellular RNAs were extracted and the mRNA levels of ALK-2, ALK-3, BMPRII 
(A), Smad6 and Smad7 (B) were examined by qPCR.  The expression levels of 
target genes were standardized by the RPL19 level in each sample.  Results are 
shown as means ± SEM of data from at least three independent experiments with 
triplicated samples (A: n=12; B: n=15).  Statistical analysis was performed by 
the unpaired t-test (A) and ANOVA (B).  P values <0.05 were accepted as 
statistically significant.  *P < 0.05 vs. between the indicated groups.  Values 
with different superscript letters are significantly different at P < 0.05.  
 
Fig. 5. Functional interrelationship between orexin A and BMP-4 activities 
in pituitary lactotrope cells.  Orexin A inhibited BMP-4-induced PRL 
expression via OX1R on GH3 cells.  Orexin A also suppressed FSK-induced 
PRL expression by inhibiting endogenous BMP action.  Orexin A inhibited BMP-
4-induced Smad1/5/9 phosphorylation and Id-1 transcription by downregulating 
ALK-3 and by upregulating BMP-4-induced Smad6/7, while BMP-4 suppressed 
OX1R expression.  Thus, orexin A plays an inhibitory role in PRL production 
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through suppression of BMPR signaling including endogenous BMP-4 action.  
AC, adenylyl cyclase; BMPRs, BMP receptors; FSK, forskolin. 
 
 
 
